Abstract: METHODS: In 10 HBV-monoinfected patients (9 male, mean age 47 +-11 [range 27-67] years, 6 hepatitis B e antigen-positive) with virological breakthrough during ADV treatment associated with the mutations rtN236T and/or rtA181T/V, HBV polymerase gene variants were studied during up to 24 months of consecutive monotherapy with TDF by population sequencing, line probe assay and clonal analysis.
Abstract: To assess the clinical relevance of this cross-resistance, we studied the evolution of HBV polymerase gene variants in patients with genotypic resistance against ADV (rtN236T and/or rt<
Comparison of rescue strategies in lamivudine-resistant patients with chronic hepatitis B.
Abstract: Additionally, the strategy of switching to ADV monotherapy induced more single rtA181T mutations.
[Clinical characteristics and effect of secondary individualized therapy in chronic hepatitis B patients infected with the rtA181 mutation hepatitis B virus].
Abstract: RESULTS: The rtA181T mutation was found in 64.8% (35/54) of patients with rtA181 mutation HBV.
Abstract: The serological index was determined for carriers of the rtA181T/V mutation.
Abstract: The serum HBsAg level was higher in carriers of the rtA181T mutation than in carriers of the rtA181V mutation (3.80+/-0.45 vs.
[Clinical analysis of hepatitis B virus mutations related to adefovir dipivoxil among patients with chronic hepatitis B virus infection in eastern Zhejiang province].
Abstract: However, long-term use of NAs increases the possibility of developing drug-resistant viral mutations such as the HBV rtA181T/sW172 mutation, which increases the risk of HCC recurrence.
Introduction: Another mutant, rtA181T, may arise during prolonged LAM therapy, conferring cross resistance to ADV.
Introduction: Importantly, since the HBV S and polymerase genes overlap with each other, a great proportion of patients with the rtA181T mutation also carry the SW172 nonsense mutation, resulting in truncation of the preS/S reading frames,
Biological characteristics of the rtA181T/sW172* mutant strain of Hepatitis B virus in animal model.
Introduction: The rtA181T mutation causes drug resistance to adefovir (ADV) clinically .
Method: A point mutation (rtA181T) in the RT region replacing Alanine (A) 181 with Threonine (T) was introduced via site-directed mutagenesis (QuikChange mutagenesis kit, Stratagene) according to the manufacturer's instructions using the forward primer: 5'-CAGCCCGTTTCTCCTGACTCAGTTTACTAGTGC-3' and the reverse primer: 5'-GCACTAGTAAACTGAGTCAGGAGAAACGGGCTG-3'.
Discussion: Clinically rtA181T is a common resistance mutation to ADV.
Discussion: Many studies showed that treatment of CHB patients with LAM, ADV, or LdT could result in the emergence of the HBV rt
Hepatitis B virus rtA181T/sW172non-stop mutation may increase resistance fold to adefovir- and entecavir-resistant mutants compared to rtA181T/sW172* mutation.
Result: Compared to wild type, the rtA181T/sW172* mutant strain showed an approximately 0.8 log reduction on day 1, 2.6 log reduction on day 3, 1.5 log reduction on day 5, and 0.7 log reduction on day 7 in serum HBV DNA titers.
Result: However, the HBV DNA replication intermediates levels of the HBV mutant rtA181T/sW172* were detectable from day 1 to day 15 and peaked on day 3 and day 5 (Figure 3B).
Result: In order to investigate the transcriptional character of the HBV rtA181T/sW172* mutant strain, HBV RNA levels in mouse liver were evaluated by northern blotting
Clonal evolution of hepatitis B virus polymerase gene mutations during lamivudine-adefovir combination treatment.
PMID: 23197889
2012
World journal of gastroenterology
Abstract: The rtA181V/T mutations were not suppressed by the LMV-ADV combination therapy.
Abstract: The rtA181V/T mutations were predominantly identified during the ADV treatment in the LMV-resistant patients.
Abstract: Thirty-nine of 64 clones showed an rtA181V/T mutation and six clones showed combined mutations in rt181 and rt236.
Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma.
Abstract: Of the NA resistance-associated mutants, A181T mutant significantly increases the risk of HCC development during the subsequent course of NA therapy.
Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection.
Result: Of the resistance mutations detected in patients who received monotherapies, rtM204I
Table: A181T/S
Table: A181T/V
Table: A181T
Discussion: The rtV84M, rtA181T and rtV214A were more common in LAM- and/or ADV-treated patients.
Discussion: To date, reports on clinical MDR HBV strains are restricted to double resistance against LAM and ADV [23, 46, 47, 48, 49, 50], if rtA181T/V cross-resistance alone and anti-HBs immunoglobulin resistance are excluded.
HBV mutation literature information.
PMID: 
2012
Antiviral therapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT